The hypermethylation of p16 gene exon 1 and exon 2: potential biomarkers for colorectal cancer and are associated with cancer pathological staging

Table 2 The relationship between CRC clinicopathological features and p16 exon 1/2 hypermethylation

Variables	N	p16 exon 1 hypermethylation (n; %)		P-value	p16 exon 2 hypermethylation (n; %)		P-value
Variables	N	Negative	Positive	P-value	Negative	Positive	P-value
Gender
Female	12	6 (50%)	6 (50%)	1.000	8 (66.7%)	4 (33.3%)	0.264
Male	18	10 (55.6%)	8 (45.4%)	1.000	7 (38.9%)	11 (61.1%)	0.264
Age
≤ 55 years	15	6 (40%)	9 (60%)	0.272	6 (40%)	9 (60%)	0.466
> 55 years	15	10 (66.7%)	5 (33.3%)	0.272	9 (60%)	6 (40%)	0.466
Differentiation
Low	6	1 (16.7%)	5 (83.3%)	0.072	1 (16.7%)	5 (83.3%)	0.169
Moderate-High	24	15 (75%)	9 (25%)	0.072	14 (58.3%)	10 (41.7%)	0.169
pT stage
pT1–2	8	6 (75%)	2 (25%)	0.226	7 (87.5%)	1 (12.5%)	0.035*
pT3–4	22	10 (45.5%)	12 (54.5%)	0.226	8 (36.4%)	14 (63.6%)	0.035*
pN stage
pN0	13	10 (76.9%)	3 (23.1%)	0.033*	8 (61.5%)	5 (38.5%)	0.462
pN1–2	17	6 (35.3%)	11 (64.7%)	0.033*	7 (41.2%)	10 (58.8%)	0.462
Dukes stage
A-B	13	10 (76.9%)	3 (23.1%)	0.033*	8 (61.5%)	5 (38.5%)	0.462
C-D	17	6 (35.3%)	11 (64.7%)	0.033*	7 (41.2%)	10 (58.8%)	0.462

ISSN: 1471-2407